Summary In order to determine whether mammary gland differentiation, which is known to protect this organ from chemically induced carcinogenesis, can be stimulated in virgin rats by administration of a progestagenic agent, medroxyprogesterone acetate (MPA) was given to 300 Sprague-Dawley virgin rats, which at the ages of 45, 55, 65 and 75 days, groups I, II, III and IV respectively, had implanted an MPA pellet of 0.5mg (low dose-LD) or 5.0mg (high dose-HD). Pellets were removed after 21 days, and 21 days later five animals per group were killed for evaluation of mammary gland development. The remaining animals received 8mg 7,12-dimethylbenz(a)-anthracene (DMBA) per lOOg body weight, and were killed after 24 weeks for evaluation of tumour incidence. Both age and treatment affected mammary gland structure and had a significant interaction in the proportion of terminal end buds (TEBs) present. The number of TEBs decreased as a function of age; treatment at both LD and HD did not modify the proportion of TEBs in groups I and III; LD decreased their percentage in group II, and both doses markedly increased TEB percentage in group IV animals. MPA LD treatment did not affect overall tumour and adenocarcinoma incidence although group IV animals developed greater incidences than their respective controls. MPA HD treated rats were 2.45 times more likely to develop tumours than their respective controls. Adenocarcinoma incidence had a significant positive correlation with the percentage of TEBs present. It was concluded that this progestagenic agent did not increase the risk of carcinoma development when administered to virgin rats at the clinical dose used for contraception. However, a 10-fold dose increase resulted in a higher tumorigenic response.
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The development of mammary tumours induced in rats by chemical carcinogens is inhibited if carcinogens are inoculated after pregnancy and lactation (Dao et al., 1960; Russo et al., 1979 Russo et al., , 1982 Russo & Russo, 1987) . The protective effect induced by pregnancy and lactation is permanent, since administration of 7,1 2-dimethylbenz(a)anthracene (DMBA) to parous rats when the glands have regressed from lactational hyperplasia to a resting stage fails almost completely to induce mammary carcinomas (Russo & Russo, 1978a ,b, 1987 . These observations indicate that it is not the transient hormonal status occurring during pregnancy and lactation that protects the mammary gland, but the permanent changes induced by the reproductive phenomenon in both gland structure and in the biological properties of the glandular epithelium (Ciocca et al., 1982; Russo et al., 1977) . Therefore, in devising strategies for breast cancer prevention, a logical approach is to stimulate mammary gland differentiation before exposure to a carcinogen by physiological mechanisms mimicking gestation. It is known that mammary gland development and differentiation are under the control of pituitary hormones. Decreased tumour incidence has been observed when mammary growth has been prestimulated by hypothalamic lesions or pituitary grafting Welsch et al., 1968) . Ovarian hormones, namely oestrogens, stimulate growth of the mammary epithelium (Daniel et al., 1987; Haslam, 1988b; Welsch et al., 1979) , and progesterone determines the formation of alveoli (Freeman & Topper, 1978) . Since combinations of oestrogens and progestagens are commonly used for contraception (Fechner, 1977; Russo et al., 1985a Russo et al., , b, 1986a Welsch & Meites, 1969) We consider the induction of rat mammary carcinomas with the chemical carcinogen DMBA to be an adequate experimental model that mimics the human situation; its study has allowed us to understand better the pathogenesis of the disease and the factors that regulate the susceptibility of the mammary gland to carcinogenesis, and to prevent the development of mammary carcinoma by means of only one pregnancy before carcinogen administration (Russo & Russo, 1980a , b, 1986 Russo et al., 1982) . This protection is mediated by elimination, through differentiation, of foci of high cellular proliferation, which are more prone to bind carcinogenic agents (Russo & Russo, 1987) . The importance of this process is emphasised by the definitive correlation found between the carcinogenic potency of polycyclic aromatic hydrocarbons such as DMBA and their interaction with tissue nucleophiles after metabolic activation and binding to DNA (Brookes & Lawley, 1964; Duncan et al., 1969; Huberman et al., 1972; Huberman & Sachs, 1974 , 1977 . The extent of polycyclic aromatic hydrocarbon binding to DNA is regulated by the rate of DNA synthesis (Brookes & Lawley, 1964) , which depends upon the age and reproductive history of the subject Janns & Ben, 1978; Tay & Russo, 1981) . Based upon this knowledge, and upon the observation that the mostly oestrogenic hormone combination norethynodrel-mestranol exerts a truly protective effect from chemically induced carcinogenesis (Russo & Russo, 1986 Russo et al., 1985a Russo et al., , b 1986a Welsch & Meites, 1969) , we considered it important to determine what influence the treatment of virgin rats with the purely progestagenic agent medroxyprogesterone acetate (MPA) would have. This work was designed to test the effect of MPA on the structure and rate of cell proliferation of the virginal gland, whether it protected the organ from DMBA induced carcinogenesis and whether there is a critical dose and age for administering this hormonal agent in order to induce a protective degree of gland differentiation. These questions were addressed to determine whether this injectable progestagen, which is used by millions of women worldwide (Garza-Flores et al., 1985; Gray & Robertson, 1975; Schwallie, 1974; Schwallie & Mohberg, 1977; Sun, 1982) , could also be used in breast cancer prevention. (Garza-Flores et al., 1985) . The second group of experimental animals had implanted a 5.0mg MPA pellet, or pharmacological dose, which was a 10-fold increase above the physiological dose; it was identified as high dose (MPA HD). The pellets had a 21-day hormone release period. Control animals received cholesterol pellets. All pellets were implanted s.c. in the interscapular area using a 10 gauge steel trocar (Innovative Research of America, Rockville, MD) to animals under light ether anaesthesia.
The number of animals per group, the length of treatment and the selection of two doses of hormones was designed following the guidelines set at the Second International Symposium of the Society of Toxicologic Pathologists on Design of Carcinogenesis Studies (1983).
Experimental protocol Both control and experimental animals in the four groups had the pellets left in place for 21 days, then the remainders of the pellets were removed and weighed. Hormone release was calculated from weight lost by the pellets, and was estimated to be 0.014+0.010mgkg-day-1. The animals were left undisturbed for an additional 21 days to allow for the mammary gland parenchyma to return to a resting stage (Ciocca et al., 1982) . At this time five animals per group were randomly selected for study of cell kinetics and mammary gland structure; they constituted the 0 time controls. The remaining animals received carcinogen for the study of tumour development. Study of 0 time controls and administration of DMBA for carcinogenic response determination were carried out 21 days after pellet removal, and therefore the actual age of the animals in each group was 87, 97, 107 and 117 days respectively at the times both of collection of mammary glands for the study of gland structure and cell kinetics, and of carcinogen administration.
Effect of treatment on mammary gland structure Forty-two days after pellet implantation, five animals from each of the groups were killed and the mammary glands were removed attached to the skin pelt, stretched on a corkboard, fixed in 10% neutral buffered formalin and processed for whole mount preparation as described by Russo et al. (1988a) . Mammary gland development was evaluated by a count under a stereomicroscope of the number of terminal structures, namely terminal end buds (TEBs), terminal ducts (TDs) and alveolar buds (ABs); alveolar buds were counted together with lobules. The terminal structures were counted along the entire peripheral area of the mammary parenchyma of each gland, by applying criteria previously described (Russo, 1983; Russo & Russo, 1978b , 1980b ) and expressed as a percentage of the total number of structures counted. We have previously described the morphology of the mammary gland as composed of ductal structures with variable lateral branching ending in TEBs, TDs, ABs or lobules (Russo & Russo, 1978a ,b, 1987 Russo et al., 1979 Russo et al., , 1982 , and have also reported that mammary glands located in the thoracic region develop at a different rate from those located in the abdominal region (Russo et al., 1986b; Russo & Russo, 1987) . Since this asynchronous development appeared to be responsible for the higher tumorigenic response of these glands after carcinogen administration, we focused our study on mammary glands located in the thoracic region. Quantitative evaluation of abdominoinguinal mammary gland development has been published elsewhere (Russo et al., 1985a (Russo et al., ,b, 1986a Russo & Russo, 1987 (Russo et al., 1988a) . Microscopic lesions identified under the stereomicroscope were photographed, dissected and embedded in paraffin for histological correlation. Grossly palpable tumours were fixed in 10% buffered formalin and processed for light microscopic examination. All palpable and microscopic tumours identified in whole mount preparations were sectioned at 5 pm thickness and stained with Haematoxylin and Eosin. Tumours were classified by applying the criteria developed in the consensus on classification of rat mammary tumours (Russo et al., 1988b) .
Animals that died within 24-48 h of DMBA administration due to adrenal necrosis or those that died without a complete autopsy, and the mammary glands and tumours of which were not examined histologically, were deleted from the study.
Statistical analysis
The effects of age and MPA treatment at both doses on the change in body weight and on the percentage of mammary gland terminal structures (TEBs, TDs and ABs) were analysed using a two factor analysis of variance (Kleinbaum & Kupper, 1978) . A multiple range test was used for posthoc comparison of means of effects. Bonferroni's technique was used to adjust for post-hoc comparison of group means (Zar, 1984) .
The proportions of DMBA-induced tumours and DMBAinduced adenocarcinomas were analysed using a logistic regression (Fleiss, 1981) . The logistic regression model for dichotomous dependent variables predicts the probability that a rat with given characteristics (i.e. MPA dose, percentage of TEBs and age) will develop tumours. Tumour development is described in terms of the odds-ratio, which is the ratio of the proportion of rats with tumours in the hormonally treated experimental group and the proportion of rats with tumours in the control group, and is computed for characteristics significant in the logistic model. A 95% confidence interval is given for these estimates (Fleiss, 1981) .
Pearson's correlation coefficient (Zar, 1984) was used to measure the association between the percentage of TEBs and the number of adenocarcinomas observed for each group.
Results

Body weight
The animals in the four groups differed in initial body weight, exhibiting a natural increase with age (Table I) (Figure 1) . Analysis of data revealed a natural decline in susceptibility to carcinogenesis with increasing age at the time of carcinogen administration. The incidence of tumours in general declined and the tumour latency period lengthened in control animals treated with cholesterol pellets after the age of 45 days and subsequent carcinogen treatment (Table III) . Age (L.R. = 10.90, d.f. = 3, P=0.0123) and treatment (L.R.=6.59, d.f.=2, P=0.037) were both significant factors in predicting the probability of developing a tumour using a logistic regression model, but there was no interaction present.
There was no difference in the probability of developing a tumour between control and low dose treated groups. Rats treated with a high dose of MPA, on the other hand, were 2.45 times more likely to develop a tumour than their age matched controls, with 95% confidence intervals of 1.103 and 5.451. Younger rats appeared to be more susceptible to tumorigenesis (Table III, Figure 1) . The odds of a group II animal developing a tumour were 0.197 compared to group I Figure 2 ) it was observed that their incidence was lowest in group II MPA LD treated animals, and second lowest in Figure 2 ). Even though in group IV control adenocarcinoma incidence was lower than in any other control group, a two-fold increase over the respective controls occurred in groups IV MPA LD and HD treated animals; no change with respect to the controls was observed in MPA LD or HD treated group I animals or in HD treated groups II and III animals (Table III, Figure 2) . When correlated by dose-age groups, the incidence of adenocarcinomas was significant and positively correlated with the average percentage of TEBs (r=0.644, d.f.=10, P=0.026). Average percentage of TDs and ABs for the 12 dose-ages did not significantly correlate with the incidence of adenocarcinomas.
Discussion
The susceptibility of the mammary gland to chemically induced carcinogenesis is considerably diminished or abolished by hormonally induced differentiation of this organ; this phenomenon is mediated by either pregnancy (Russo & Russo, 1986 Russo et al., 1982) or exogenously administered hormones, either contraceptive agents such as norethynodrel-mestranol or the placental hormone chorionic gonadotropin (Russo & Russo, 1987) . These observations led us to test whether treatment of virgin rats with the progestagenic agent MPA before the administration of DMBA protected the mammary gland from neoplastic transformation, and whether this compound was more efficient than the estrogenic contraceptive norethynodrel-mestranol (Russo et al., 1988a) . We observed that treatment with the dose clinically used for contraception in Depo-Provera (GarzaFlores et al., 1985) affected the mammary gland structure and its tumorigenic response differently from treatment with a 10-fold higher or pharmacological dose. MPA low dose treatment resulted in statistically significant reductions in percentage of TEBs only in animals whose treatment started at age 55 (Group II), which correlated with the observed lower tumour and adenocarcinoma incidence. However, although age and treatment were significant factors in predicting tumour development, there was no interaction present and low dose treatment did not modify the probability of a rat developing a tumour. Rats treated with the high dose, on the other hand, were 2.45 times more likely to develop a tumour than controls. The effect of both MPA LD and MPA HD on mammary gland structure was manifested in the 75-day-old animals as an inhibition of mammary gland differentiation, namely inhibition of the progression of TEBs to ABs and of these to lobules, which resulted in a relative increase in the number of TEBs over BJC D the number normally found in age-matched animals. These structural changes had a statistically significant correlation with the incidence of adenocarcinomas developed after exposure to carcinogen. These results contrasted markedly with those observed in rats treated with both low and high dose norethynodrel-mestranol (Russo et al., 1988a) , in which the hormonal treatment resulted in a dose-dependent significant reduction in percentage of TEBs and a concomitant reduction in DMBA-induced tumour and adenocarcinoma incidence. A protective effect of ovarian hormones has been reported by various authors (Kledzik et al., 1974; Stern & Mickey, 1969; Welsch & Meites, 1969) . Huggins et al. (1962) observed that 17B-oestradiol had a protective effect when given in combination with progesterone, decreasing cancer incidence when the hormones were administered 15 days post-DMBA instillation, whereas pregnancy and progesterone alone accelerated tumour growth. Increased tumour incidence as a consequence of progestagenic hormonal treatment has been reported in other species such as beagle dogs, which develop malignant and metastatic mammary tumours after treatment with low and high doses of depot MPA, and rhesus monkeys develop endometrial carcinomas after treatment with high dose of this hormone (Concannon et al., 1980; Fowler et al., 1977; Frank et al., 1979) . In Balb/c mice, depot MPA treatment induces a high incidence of invasive mammary adenocarcinomas (Lanari et al., 1986a, b) . All of these studies, however, attest to the carcinogenic effect of the hormone per se; ours is the first study that reports the influence of MPA on mammary gland structure before exposure to DMBA, thus acting as a modifier of the response of this organ to a chemical carcinogen. It remains to be elucidated whether the effect of this acetoxyprogesterone derivative, which is qualitatively similar to but more potent than progesterone (Edgren, 1969) on mammary gland development, is mediated by its progestagenic, androgenic or synandrogenic effects (MacLaughlin & Richardson, 1979) .
The focus in recent years has been primarily on the role of oestrogens in the development and promotion of growth of neoplasias in secondary sex structures, including the breast (Van Boagert, 1978a, b) . Progesterone, in contrast, is considered to be a neutraliser of oestrogen and oestrogenic action. However, there is evidence that progesterone stimulates the incorporation of labelled thymidine into human mammary ductal epithelial cells (Van Boagert, 1978a, b) , mainly the epithelial cells of the interlobular ducts. Those findings are consistent with the elevation in DNA-LI observed in MPA treated animals (Russo & Russo, 1988) ; however, this is not a universal phenomenon, but varies in the different compartments of the gland and with the age of the animal, which suggests that local regulatory factors or hormone receptor levels might be modulating the response of the glandular epithelium to this hormone. Our observations that animals treated at the age of 45 days responded differently to MPA treatment from animals treated at older ages are supported by the observations that the effect of progesterone on mammary gland epithelial proliferation differs depending upon the age of the animal (Haslam, 1988a) , since the TEB of ovariectomised 5-week-old mice responds with cell proliferation to oestrogen (Daniel et al., 1987; Haslam, 1988b ) whereas progesterone strongly stimulates DNA synthesis in 10-week-old animals (Haslam, 1988a) . It is possible to postulate that the same mechanisms are operating in the rat, since the response to treatment varied with age. In the DMBA rat mammary carcinoma model, progesterone, like oestradiol, reduces the latency period and increases the size and number of tumours developed when it is administered during the latent period following DMBA (Huggins et al., 1958; Jabara, 1967; Kelly et al., 1977) , although progesterone does not maintain hormone dependent carcinomas in castrated rats (Van Boagert, 1978b) .
The possible role of progestagenic contraceptives in the aetiology of breast cancer is far from being clarified. Nevertheless, epidemiological studies have linked the use of high progestagen contraceptive agents administered before a full term pregnancy to a higher risk of developing breast (Pike et al., 1981 (Pike et al., , 1983 ) and cervical cancer (WHO Collaborative Study of Neoplasia and Steroid Contraceptive, 1984) . Epidemiological observations in general tend to consider that combination oral contraceptives have no influence on breast cancer risk (Rosner & Lane, 1986; Thomas, 1978; Vessey et al., 1979; Wang & Fentiman, 1985) , a finding confirmed by experimental data showing that the combination compound norethyndrel-mestranol, which in the rat is mostly oestrogenic, has a protective effect from chemically induced carcinogenesis (Russo et al., 1985a (Russo et al., , b, 1986a Russo & Russo, 1986 Stern & Mickey, 1969; Welsch & Meites, 1969) , whereas the progestagenic compound MPA tends to increase tumour incidence. Our studies allowed us to conclude that in the DMBA-rat mammary gland system, MPA treatment at the dose used for contraception does not significantly affect mammary gland development, and therefore does not modify the response of the organ to the administration of a chemical carcinogen, whereas a 10-fold increase in dose results in inhibition of gland differentiation in the group treated at 75 days of age, with an increase in number of targets and a consequent increase in tumour incidence. These results emphasise the need for further investigation on the role of natural and synthetic progestagenic agents on mammary gland development and differentiation, especially with regards to the influence of age and/or receptor content in the response of the gland to these hormones, and how they will interact in the modulation of the gland's susceptibility to carcinogenesis.
